Curi Bio offers fully characterized, quality-guaranteed iPSC-derived cell models for sale or licensing to support drug discovery, disease modeling, and translational research. Select models include isogenic pairs for controlled comparative studies.
iPSC-derived myoblast lines spanning healthy donors, patient-derived disease models, and CRISPR-corrected isogenic pairs — for DMD, DM1, and XLMTM research.
iPSC-derived cardiomyocyte lines for cardiac disease modeling and translational studies, including a CRISPR-corrected isogenic pair for hypertrophic cardiomyopathy.
Motor neuron and neuromuscular junction media systems are available today. iPSC-derived motor neuron cell lines — including a ChR2-optogenetic line — are in development for the Fall 2026 launch.
Licensing Only
30 curated iPSC lines representing North American genetic diversity. Ideal for population disease modeling, pharmacogenomics, and evaluating varied drug responses.
Our team can discuss custom cell line development, isogenic pair generation, and licensing terms for the iPSC Diversity Panel.
